Floatz logo

Abituzumab

Colorectal and Ovarian Cancer Patients With Liver Metastases

Merck KGaA, Darmstadt, Germanymonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Colorectal and Ovarian Cancer Patients With Liver Metastases cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Abituzumab is also rated in:

metastatic prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
55 / 100
View asset →
metastatic carcinoma in the boneDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →